Teva raised its forecasts, and its three main branded drugs grew 33% in local currency, supporting a stronger business outlook. Generics sales fell 16%, and Medicare price talks are expected to pressure Austedo in 2027, but brand growth and the higher forecasts matter more.
Growth in Teva’s branded medicines and improved profit on sales support the stronger forecast. That growth has helped make up for weaker sales of generic drugs. Medicare price talks are expected to pressure Austedo in 2027, but Teva expects strong demand for the drug.
Follow Teva Pharmaceutical Industries Ltd. (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEVA